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Abstract. This paper describes a method for a model-based analysis
of clinical safety data called multivariate Bayesian logistic regression
(MBLR). Parallel logistic regression models are fit to a set of medically
related issues, or response variables, and MBLR allows information
from the different issues to “borrow strength” from each other. The
method is especially suited to sparse response data, as often occurs
when fine-grained adverse events are collected from subjects in studies
sized more for efficacy than for safety investigations. A combined anal-
ysis of data from multiple studies can be performed and the method
enables a search for vulnerable subgroups based on the covariates in
the regression model. An example involving 10 medically related issues
from a pool of 8 studies is presented, as well as simulations showing
distributional properties of the method.
Key words and phrases: Adverse drug reactions, Bayesian shrinkage,
drug safety, data granularity, hierarchical Bayesian model, parallel lo-
gistic regressions, sparse data, variance component estimation.
1. INTRODUCTION
This paper introduces an analysis method for safe-
ty data from a pool of clinical studies called multi-
variate Bayesian logistic regression analysis (MBLR).
The dependent or response variables in the MBLR
are defined at the subject level, that is, for each sub-
ject the response is either 0 or 1 for each safety issue,
depending on whether that subject has been deter-
mined to be affected by that issue based on the data
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available at the time of the analysis. Safety issues
can include occurrence of specific adverse events as
well as clinically significant lab tests or other safety-
related measurements. The predictor variables, as-
sumed to be dichotomous or categorical, are all as-
sumed to be observable at the time of subject ran-
domization. The analysis is cross-sectional rather
than longitudinal, and does not take into account
the variability, if any, of the length of time different
subjects have been observed. The primary predictor
is study Arm, assumed to be dichotomous with val-
ues “Treatment” or “Comparator.” Other subject-
level covariates may be included, such as gender or
age categories, or medical history variables. One fea-
ture of the MBLR approach is that the interactions
of treatment arm with each of the other covariates
are automatically included in the analysis model.
Data from a pool of multiple studies (having com-
mon treatment arm definitions) may be included in
the same analysis, in which case the study identifier
would be considered a subject covariate. Analyses
involving a pool of studies are similar in spirit to
a full-data meta-analysis.
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Estimation of effects involves a hierarchical Bayesi-
an algorithm as described below. There are two pri-
mary rationales for the Bayesian approach. First,
data concerning safety issues are often sparse, lead-
ing to high variability in relative rates of rare events
among subject subgroups, and the smoothing inher-
ent in empirical Bayes shrinkage estimates can al-
leviate problems with estimation of ratios of small
rates and the use of multiple post-hoc comparisons
when encountering unexpected effects. Second,
MBLR fits the same analytical model to each re-
sponse variable and then allows the estimates of ef-
fects for the different responses to “borrow strength”
from each other, to the extent that the patterns of
coefficient estimates across different responses are
similar. This implies that the different safety issues
should be medically related, so that it is plausible
that the different issues have related mechanisms
of causation or are different expressions of a broad
syndrome, such as being involved in the same body
system, or different MedDRA terms in nearby lo-
cations in the MedDRA hierarchy of adverse event
definitions. The goal is to assist with the problem
of uncertain granularity of analysis. The question
of how to classify and group adverse drug reaction
reports can be controversial because different assign-
ments can change the statistical significance of count
data treatment effects, and methods and definitions
for comparing adverse drug event rates are not well
standardized (Dean, 2003). Sometimes the amount
of data available for each of the related safety is-
sues is too little for reliable comparisons, whereas
doing a single analysis on a transformed response,
defined as present when any of the original issues
are present, risks submerging a few potentially sig-
nificant issues among others having no treatment as-
sociation. The Bayesian approach is a compromise
between these two extremes.
The proposed methodology is not intended to re-
place or replicate other processes for evaluating safe-
ty risk but rather to support and augment them.
In spite of the formal modeling structure, its spirit
is more a mixture of exploratory and confirmatory
analysis, a way to get a big picture review when
there are very many parameters of interest. The re-
sulting estimates with confidence intervals can pro-
vide a new approach to the problem of how to best
evaluate safety risk from clinical studies designed to
test efficacy.
This paper describes the statistical model and the
estimation algorithms used in a commercial imple-
mentation of MBLR. There is also some discussion
of alternate models and algorithms with reasons for
our choices. An example analysis utilizes data from
a set of clinical studies generously provided by an
industry partner, and a simulation provides infor-
mation on the statistical properties of the method.
2. THE BAYESIAN MODEL FOR MBLR
As with standard logistic regression, MBLR pro-
duces parameter estimates interpretable as log odds,
and provides upper and lower confidence bounds for
these estimates. The method is based on the hier-
archical Bayesian model described below. Identical
regression models (i.e., the same predictor variables
for different response variables) are estimated as-
suming that the relationships being examined are
all based on the same underlying process. The re-
sponse variables represent issues comprising a po-
tentially common safety problem and the underlying
process is an adverse reaction caused by the treat-
ment compound. The regression models are various
examinations of relationships between subgroups de-
fined by the covariates and the response issues. The
Bayesian estimates of treatment-by-covariate inter-
actions are conservative (estimates are “shrunk” to-
ward null hypothesis values), in order to reduce the
false alarm due to high variance in small sample
sizes. This conservatism is a form of adjustment for
multiple comparisons.
It is natural to desire a comparison of MBLR with
a more standard analysis, which, for the present pur-
pose, means a logistic regression model where the
estimates for the different responses are not shrunk
toward each other, and where interactions between
treatment and other covariates are not being esti-
mated. However, it can often happen, with sparse
safety data involving rare adverse events and the use
of other predictors in addition to the treatment ef-
fect, that standard logistic regression estimation can
fail, because the likelihood function has no unique
finite maximizing set of parameters. Gelman et al.
(2008) discuss this problem, caused by what they
call separation and sparsity, and suggest the auto-
matic use of weakly informative prior distributions
as a default choice for such analyses. Along the lines
of the Gelman et al. (2008) suggestion, we will com-
pare MBLR to a “weak Bayes” method that corre-
sponds to setting certain variance components (that
are estimated by MBLR) to values selected to be so
large that the resulting estimates would be virtually
the same as those of standard logistic regression if
the data are not so sparse as to be unidentifiable.
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This comparison method will be denoted regularized
logistic regression (RLR).
The event data can be considered as a K-column
matrix Y , with a row for each subject and a column
for each issue, and where Ysk = 1 if subject s experi-
enced issue k, 0 otherwise. Since all subject covari-
ates are assumed categorical, we will use a grouped-
data approach, where there are ni subjects (i =
1, . . . ,m) that have identical covariates and treat-
ment allocation in the ith group, and where Nik of
these subjects experienced issue k.
MBLR requires the inclusion of the treatment arm
and of one or more additional predictors in the model,
where all predictors are categorical.
Across the set of issues a single regression model is
used. If there are J predictors excluding Treatment,
and the jth predictor has gj categories, j = 1, . . . , J ,
then there will be G =
∑
gj subgroups analyzed.
The model will usually have 2G+2− 2J degrees of
freedom and estimation is performed by constrain-
ing sums of coefficients involving the same covari-
ate to add to 0. The Bayesian methods presented
here allow estimation in the presence of additional
collinearity of predictors, in which case the com-
puted posterior standard deviations would then re-
flect the uncertainty inherent in a deficient design.
For the ith group of subjects, the modeled prob-
ability of experiencing issue k is Pik, where
Pik = 1/[1 + exp(−Zik)] and where(1)
Zik = α0k +
∑
1≤g≤G
Xigαgk
(2)
+ Ti
(
β0k +
∑
1≤g≤G
Xigβgk
)
.
The G columns of X define the G dummy vari-
ables for the J covariates, and Ti is an indicator for
the treatment status of the ith group. The values
of αgk (g = 0, . . . ,G; k = 1, . . . ,K) define the risk of
issue k for the comparator subjects. As mentioned
above, the sums
∑
g αgk = 0, where the sums are
over the categories of each covariate for each k. The
more natural quantities (α0k+αgk) are the log odds
that a comparator subject in subgroup g will ex-
perience issue k, g = 1, . . . ,G, averaged across the
categories of other predictors not defined by sub-
group g.
Concerning treatment effects, the quantities (β0k+
βgk) are the estimated log odds ratios for the risk
of issue k (treatment versus comparator) that sub-
jects in group g experience, g = 1, . . . ,G, averaged
across the categories of other predictors not defined
by subgroup g. The sums
∑
g βgk are constrained
just as the α’s were.
If G is large, there will be many possible subgroup
comparisons, and, since these confidence intervals
have not been adjusted for multiple comparisons,
caution is advised in interpreting the largest few of
such observed subgroup estimates. The MBLR es-
timates of these quantities are designed to be more
reliable in the presence of multiple comparisons be-
cause subgroup-by-treatment interaction effects are
“shrunk” toward 0 in a statistically appropriate way,
and there is also a partial averaging across issues, so
that subgroup and treatment effects and subgroup-
by-treatment interactions can “borrow strength” if
there is an observed similar pattern of treatment
and subgroup effects in most of the K issues being
analyzed. When configuring a multivariate Bayesian
logistic regression, the analyst should try to select
those issues for which there is some suspicion of
a common medical mechanism involved. If the Bayes-
ian algorithm does not detect a common pattern of
subgroup effects, then the Bayesian algorithm will
perform little partial averaging across issues, be-
cause corresponding variance component estimates
will be large.
The Bayesian model is a two-stage hierarchical
prior specification:
αgk|Ag ∼N(Ag, σ
2
A),
(3)
k = 1, . . . ,K;g = 1, . . . ,G,
β0k|B0 ∼N(B0, σ
2
0), k = 1, . . . ,K,(4)
βgk|Bg ∼N(Bg, σ
2
B),
(5)
k = 1, . . . ,K;g = 1, . . . ,G,
Bg ∼N(0, τ
2), g = 1, . . . ,G.(6)
The prior distributions of α0k, k = 1, . . . ,K, and
of Ag, g = 1, . . . ,G, and of B0 are assumed uniform
within (−∞,+∞). Equations (3)–(5) embody the
assumption that coefficients for the same predictor
across multiple issues cluster around the predictor-
specific values (A1, . . . ,AG,B0, . . . ,BG) with the de-
gree of clustering dependent on the magnitude of
three variances (σ2A, σ
2
0, σ
2
B). If any of these vari-
ances are near 0, there will be a tight cluster of the
corresponding regression coefficients across the K
responses, whereas if they are large, there may be
no noticeable common pattern across k for predic-
tor g. The values of α0k correspond to the constant
terms in the regressions, and we assume no com-
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mon shrinkage of constant terms across issues, since
the absolute frequencies of the issues are not being
modeled here.
Equation (6) embodies the assumption that the
null hypotheses Bg = 0 (i.e., no treatment-by-covari-
ate interactions when averaged across responses) are
given priority in the analyses. This is the assumption
that helps protect against the multiple comparisons
fallacy when searching for vulnerable covariate sub-
groups. The value of τ2 determines how strongly to
shrink the G prior means Bg toward 0 in the second
level of the prior specification.
The four standard deviations (σA, σ0, σB, τ) have
prior distributions assumed to be uniform in the
four-dimensional cube 0≤ σ, τ ≤ d. Their joint pos-
terior distribution is approximated by a discrete dis-
tribution for computational convenience, as described
below. The posterior distribution of the coefficients
{Ag,Bg, αgk, βgk} is defined as a mixture of the dis-
tributions of the coefficients conditional on the pos-
sible values of the variance components. The method
produces an approximate variance–covariance ma-
trix for all the coefficients, and this also allows the
estimation of standard deviations and confidence in-
tervals (credible intervals) for linear combinations
of parameters such as the quantities (β0k + βgk) de-
scribing the total treatment effect estimates for each
subgroup.
General discussion of hierarchical Bayesian regres-
sion models is available in Carlin and Louis (2000),
although the particular model (involving multiple
responses) and estimation methods used in this pa-
per are not discussed there. Searle, Casella and Mc-
Culloch [(1992), Chapter 9] also discuss related meth-
ods, including a logit-normal model somewhat sim-
ilar to this one.
3. ESTIMATION DETAILS
Estimation of MBLR Parameters
The estimation algorithm for MBLR is based on
separate maximizations of the posterior distributions
of the coefficients, conditional on the values of the
variance components. Then these posterior distri-
butions are averaged to provide an overall posterior
distribution, where the weights in the average are
determined by the Bayes factors for different val-
ues of the vector of the four variance components.
First we assume that the four standard deviations
(σA, σ0, σB , τ ) are fixed and known and consider es-
timation of the other parameters.
Estimation of Coefficients and Prior Means
Conditional on Prior Standard Deviations
There are M = 2(G+1)(K +1)− 1 such parame-
ters: 2G+ 1 prior means, (G+ 1)K values αgk and
(G+ 1)K values of βgk. However, 2J(K + 1) sums
of these parameters are defined as 0, leaving M∗ =
2(G−J+1)(K+1)−1 dimensions for estimation. It
is convenient to imagine that subjects are grouped
according to unique values of their covariates and
treatment allocation, so that the data are the sam-
ple sizes ni and the counts Nik (i = 1, . . . ,m; k =
1, . . . ,K), where i indexesm strata defined by unique
values of covariates and treatment. The joint distri-
bution of the parameters and the data can be rep-
resented as
p(A1, . . . ,AG,B0, . . . ,BG)
·
∏
k
p(α0k, . . . , αGk, β0k, . . . , βGk|{A}{B})(7)
· p({Nik}|{A}{B}{α}{β}).
The prior distributions of A1, . . . ,AG, B0 and the
{α0k} are assumed uniform over (−∞,+∞), whereas
all the remaining parameters have prior distribu-
tions as given in equations (3)–(6).
Therefore, if logL is the log posterior joint distri-
bution of all the parameters, then, up to a constant,
2 logL=−
[∑
g>0
B2g/τ
2 + (G− J) log(τ2)
]
−
[∑
g>0
∑
k
(αgk −Ag)
2/σ2A
+ (G− J)K log(σ2A)
]
−
[∑
k
(β0k −B0)
2/σ20 +K log(σ
2
0)
]
(8)
−
[∑
g>0
∑
k
(βgk −Bg)
2/σ2B
+ (G− J)K log(σ2B)
]
+2
∑
i
∑
k
[Nik log(Pik)
+ (ni −Nik) log(1−Pik)].
In (8), the terms involving log(τ2), log(σ2A) and
log(σ2B) all have a factor (G − J), rather than the
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more natural G, since there are G values {Ag} and
{Bg}. But since they are being estimated subject
to J constraints where subsets of them add to 0,
the factor (G− J) is substituted, analogous to the
way REML estimates are defined for variance com-
ponents in a frequentist analysis. For fixed variance
components, maximization of (8) with respect to all
other parameters, remembering that the Pik are de-
fined by (1) and (2), involves a relatively straight-
forward modification of the usual logistic regression
calculations. The prior means {Ag} and {Bg} are
treated analogously to the coefficients {αgk} and
{βgk} during the Newton–Raphson maximization of
logL. Each iteration involves calculation of the vec-
tor S of M first derivatives of logL with respect to
the parameters in (8) and the M ×M Hessian ma-
trix H of the negative second derivatives of logL.
The initial values of α0k are log(N+k/(n+ −N+k)),
k = 1, . . . ,K (the subscript “+” means sum over the
values of i), whereas the initial values of all other
parameters are 0.
Upon convergence of the maximization, the vari-
ance–covariance matrix of the estimated parameters
is assumed to be
V = V (σA, σ0, σB, τ) =H
−1.(9)
[Actually, the matrix H will be singular because
of the constraints that reduce the rank of H . The
interpretation of (9) is as follows. Define a subset θ∗
of M∗ parameters out of the M -vector θ, where one
parameter from each constrained subset has been
omitted, but will be constrained to be equal to the
negative of the sum of the other parameters in its
subset. Define the M ×M∗ matrix Z that converts
from θ∗ to θ, that is, θ =Zθ∗. Then (9) is interpreted
as V = Z(ZtHZ)−1Zt. The same transformation is
used during the Newton–Raphson maximization of
logL. Also, in (11b) and later, the determinant of V
is computed as the determinant of V ∗ = (ZtHZ)−1.]
The computation of V as H−1 uses the assump-
tion that the counts {Nik} are independent across
both i and k, conditional on the parameters. The
occurrence of different events in the same subject
may be connected via the parameters, but not oth-
erwise correlated in this model. If this assumption
is violated, the variances in V may be underesti-
mated. Since the M parameters include both all the
coefficients as well as their prior means, the vari-
ances in V for any one component automatically
include uncertainty due to correlation with all other
components. In particular, uncertainty in the prior
means {Ag,B0,Bg} is taken account of in the esti-
mated posterior variances of the {αgk, βgk} (up to
the accuracy of the approximate multivariate nor-
mality of the joint posterior distribution of the pa-
rameters).
Accounting for Uncertainty in the Prior Standard
Deviations
The prior distribution of the set of possible values
of (σA, σ0, σB , τ ) is assumed to be uniform within
the four-dimensional cube with limits (0, d), where
a default value of d = 1.5 is selected as discussed
below. A discrete search method approximates the
posterior distribution within this cube. Before dis-
cussing the details, consider the situation where the
prior standard deviation vector φ= (σA, σ0, σB, τ) is
assumed to be one of S discrete values φ1, φ2, . . . , φS .
Denote the vector of coefficients and prior means by
θ = (A1, . . . ,AG,B0, . . . ,BG, α01, . . . , αGK , β01, . . . ,
βGK), and assume that the maximized logL and the
estimated posterior mean and covariance matrix of θ
are (logLs, θs, Vs) if φ = φs, s = 1, . . . , S. Then the
marginal posterior distribution of θ, adjusting for
uncertainty in φ, is assumed to be multivariate nor-
mal with mean θˆ and covariance matrix V , where
θˆ =
∑
s
pisθs,(10a)
V =
∑
s
pis[Vs + (θs − θˆ)(θs − θˆ)
t],(10b)
and where pis, the posterior weight given to φ= φs,
s= 1, . . . , S, is defined by
pis = BF s/(BF 1 + · · ·+BFS),(11a)
BF s = exp(logLs)
√
det(Vs).(11b)
The quantity BF s is the (relative) Bayes factor
for the hypothesis φ = φs. The usual definition of
the Bayes factor requires the integration of the joint
likelihood over the space of all parameters not spec-
ified by the hypothesis—in this case the space of
all θ. Using the approximation of this likelihood as
proportional to a multivariate normal density with
covariance matrix Vs, and the known fact that vol-
ume under the multivariate exponential form
exp[−θt(Vs)
−1θ/2] is proportional to the square root
of the determinant of Vs, the definition of BF s is as
given in (11). The approximation (11) is the stan-
dard Laplace approximation often used for numeri-
cal integration in Bayesian methods. However, a dif-
ferent justification for computing (11b) in order to
obtain estimates for variance components is given
by the theory of h-likelihood (Lee and Nelder, 1996;
Lee, Nelder and Pawitan, 2006; Meng, 2009).
6 W. DUMOUCHEL
Selection and computation of the values
(φs, pis), s= 1, . . . , S
Representing the 4-dimensional naturally contin-
uous distribution of φ by a set of discrete points is
a challenge. Assuming a range of d = 1.5 for each
element of φ and a spacing of 0.1 would mean a grid
of S = 154 > 50,000 points, the vast majority of
which would have values of pis nearly 0. Determi-
nation of a set of just S = 33 points to represent
the approximate posterior distribution of φ is per-
formed as outlined next. A logistic transformation
is used to convert the bounded cube (0, d)4 to the
unbounded region where all four elements can range
from (−∞,+∞) by defining
λ= (λA, λ0, λB , λτ ) where
σA = d/(1 + e
−λA), σ0 = d/(1 + e
−λ0),(12)
σB = d/(1 + e
−λB ), τ = d/(1 + e−λτ ).
With this transformation, a uniform prior distri-
bution on (0, d) for each σ corresponds to a prior
distribution for each λ over the real line of f(λ)∝
σ(λ)(d − σ(λ)). The purpose of this transform is
to allow simpler search procedures that don’t have
to worry about boundary constraints, as well as to
make approximation of the posterior by a multi-
variate normal distribution more accurate. Then the
posterior density of λ is assumed to be
g(λ) = g(λA, λ0, λB, λτ )
∝ f(λA)f(λ0)f(λB)f(λτ )(13)
· exp(logLs)
√
det(Vs),
where logL and V in (13) are now functions of λ,
and the λ’s vary over (−∞,+∞).
The determination of the discrete distribution (φs,
pis), s= 1, . . . , S, is a five-step process:
Step 1: Use the method of steepest ascent to find
the value λmax that maximizes g(λ) in (13). Deriva-
tives of g are computed numerically as first differ-
ence ratios with respect to each of the four argu-
ments. The starting value for the search is λ= (0,0,
0,0).
Step 2: Construct a design of S = 33 λ-values by
adding 16 points on the surface of each of two con-
centric spheres centered at λmax. The points on the
inner sphere consist of 8 star points, where one com-
ponent of λ is λmax ± 2δ0 and the other three com-
ponents equal λmax, and 8 half-fractional factorial
points, where all components are λmax ± δ0. The
points on the outer sphere are similar to those on
the inner sphere, except that δ0 is replaced by 1.5δ0
and the fractional factorial points are from the op-
posite half fraction as the fractional factorial points
on the inner sphere. The default value of δ0 = 0.3 on
the scale of λ. Visualizing the geometry of the de-
sign, if a 4-dimensional sphere has radius 1.5 times
another, it encloses about 5 times the volume.
Step 3: The double central composite design of
Step 2 is centered but not scaled to the actual dis-
tribution g(λ). To find the appropriate scale factors
in each dimension, δ = (δ1, δ2, δ3, δ4), for a better fit-
ting design, a quadratic response surface model is fit
to values of log g(λ) across the S points of this initial
design. The fitted model is
log g(λ) = c0 +
∑
i
ciλi +
∑
i≤j
cijλiλj.(14)
Now if the quadratic model fit exactly (i.e., if g
were exactly multivariate normal), then the second-
order coefficients cij would specify the elements of
the inverse of the posterior covariance matrix of λ.
Accordingly, we get what are hoped to be approx-
imate posterior standard deviations by setting δ =
vector of square roots of the diagonal of H−1, where
2H =


2c11 c12 c13 c14
c12 2c22 c23 c24
c13 c23 2c33 c34
c14 c24 c34 2c44

 .(15)
Step 4: Next a new design like that of Step 2 is
constructed except that the δ0 used in Step 2 for all
4 dimensions is replaced by δ = (δ1, δ2, δ3, δ4) from
Step 3, so that the spheres are scaled differently in
each dimension. The values of log g(λ) are computed
for these 32 new points and a new quadratic re-
sponse surface is fit to this 33-point final design.
Let the peak of this fitted surface be denoted λfit,
which will not exactly equal λmax, and redefine δ =
(δ1, δ2, δ3, δ4) by using the coefficients from the new
quadratic response surface in (15).
Step 5: The discrete distribution defined by {λ(s),
g(λ(s)), s= 1, . . . , S} as computed in Step 4 will rough-
ly approximate the continuous distribution defined
by g(λ), but the approximation can be improved by
modifying the S = 33 probabilities to constrain the
4 means and 4 standard deviations of the discrete
distribution to exactly match the values λfit and δ
that were computed from the response surface fit
of Step 4. The final probabilities pis, s = 1, . . . , S,
are computed as the solution to the following con-
strained optimization problem:
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Find positive pi1, . . . , piS that minimize the Kul-
lback–Leibler divergence
KL=
∑
s
g(λ(s)) log[g(λ(s))/pis],
subject to the 9-dimensional constraints
(16) ∑
s
pis = 1;
∑
s
pisλ
(s) = λfit;
∑
s
pis(λ
(s) − λfit)2 = δ2,
where the last two equations are each interpreted
as 4 constraints, one for each component of λ. The
constrained minimization problem of (16) is solved
using the method of Lagrange multipliers combined
with a Newton–Raphson solution of the resulting 9
equations.
Thus, the {pis} used in (10) are the solution to (16)
rather than the more direct values in (11). They dif-
fer from (11) by incorporating the Jacobian terms
of (13) and the further modifications needed to sat-
isfy the constraints in (16). The values of {φs} used
in (10) are the back-transformations defined by (12)
of the final S = 33 points {λs} used in Steps 4 and 5.
Estimates Using Regularized Logistic Regression
(RLR)
To compare the MBLR results to standard logis-
tic regression, and still be able to avoid problems
with nonidentifiability, as discussed above, the RLR
algorithm is defined by fitting MBLR under the con-
straints
σA = 5, σ0 = 5, σB = 0.001, τ = 0.001.(17)
Setting σB and τ very close to 0 effectively con-
strains the estimates of covariate-by-treatment inter-
actions to be 0. Setting σA and σ0 to be very large pre-
vents the estimates across different response events
from shrinking toward each other The rationale for
thinking that a prior standard deviation of 5 is very
large for a logistic regression coefficient is as fol-
lows. Remembering that the coefficients are inter-
preted as logs of odds ratios, an increase of 5 in
a coefficient corresponds to a multiplicative factor
of e5 = 148.4 in an odds ratio. With respect to the
assumed normal prior distributions in equations (3)–
(6), the prior standard deviation of 5 implies that
about one-third of all estimated odds ratios are ex-
pected to be outside the range of (1/148 = 0.007,
148). This certainly seems to be well beyond the
range of expected odds ratios in any medical risk es-
timation situation. See Gelman et al. (2008) for a re-
lated discussion. [In the Bayesian setup described
above, we use as default limits for the prior standard
deviations (0, d= 1.5). Considering a prior standard
deviation to be as large as 1.5, where e1.5 = 4.5, im-
plies that about one-third of the estimated odds ra-
tios would be outside the range of (1/4.5 = 0.22,
4.5), which seems a bit of a stretch, but barely con-
ceivable.]
Using the values in (17) for the prior standard de-
viations, this alternative weak Bayesian prior method
estimates the parameters and their variances us-
ing the iterative Newton–Raphson estimation de-
scribed above. The resulting estimates are computa-
tionally reliable even if many of the response events
are sparse. Such estimates perform very little shrink-
age across response models because the prior stan-
dard deviations in equations (3)–(6) are large com-
pared to the standard errors of the (estimable) logis-
tic regression coefficients. However, the MBLR and
RLR models as formulated will not protect against
problems of estimability in case every response is
quite sparse, because of the use of an improper prior
for the prior means (A1, . . . ,AG,B0). If certain co-
variate or treatment categories are perfectly corre-
lated with every response, then one must either drop
such predictors or add additional response variables.
The Bayes factor for φ0 = (5,5,0.001,0.001) can
be computed and compared to the 33 values found
in the final grid of the Bayesian estimation described
above, which provides further evidence regarding
the prior standard deviations. In particular, large
Bayes factors against φ0 imply that the MBLR model
fits the data better than the RLR model, meaning
that there is significant evidence that either the re-
sponses have similar covariate profiles or that there
are significant covariate-by-treatment interactions.
Confidence Intervals for Odds Ratios
Let the final estimate of, for example, βgk be bgk,
so that the odds ratio point estimate is ORgk =
exp(bgk). Using the normal approximation to the
posterior distribution of the coefficients and the es-
timates of V in equation (10), 90% confidence in-
tervals (posterior credible intervals) for the corre-
sponding odds ratios are given by
OR.05 = exp[bgk − 1.645
√
v(βgk)]<OR
(18)
< exp[bgk +1.645
√
v(βgk)] = OR.95.
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For the main effects of covariates or for treatment,
these provide confidence (credible) intervals for odds
ratios of the predictor vs the response outcome. The
odds ratio comparing two categories of a multicat-
egory covariate would be found by taking the ratio
of the corresponding exponentiated coefficients.
Interpreting the interaction effects of covariates
with treatment arm is tricky, since it would involve
ratios of odds ratios. To aid in interpretation, one
can present in addition to the interaction coefficients
themselves, the sums of the treatment coefficient
plus the interaction coefficients. Confidence intervals
for these sums are formed in the usual way, taking
into account the covariances between the treatment
coefficient and the interaction coefficients. When
these sums and their confidence limits are expo-
nentiated, we get estimates and limits for subgroup
treatment-by-outcome odds ratios. These estimates
are oriented toward finding potentially vulnerable
subgroups where the adverse effect risk of treatment
is especially high.
4. DISCUSSION OF METHODS AND
ALTERNATE MODELS
The philosophy of estimation is not to try to model
the medical mechanisms perfectly, but to provide
a reliable compromise between pooling related sparse
events in order to increase the sample size, and fit-
ting separate models to each event, with the corre-
sponding loss of power due to small samples. The
selection of which issues to include in an MBLR is
important. There needs to be at least a superficial
plausibility that all or many of the selected outcome
issues might have similar odds ratios with treat-
ment and with the covariates in the model, what
Bayesians call exchangeability. Sometimes it may be
difficult to decide what other issues to include if at-
tention has focused primarily on a single and seem-
ingly unique issue such as subject death. Because it
takes several degrees of freedom to estimate a vari-
ance component, the values of some of the standard
deviations in equations (3)–(6) may be poorly esti-
mated if K and/or G are not large, but the use of
Bayes factors and the computation of the pis in (11)
and (16) allow some assessment and adjustment for
this uncertainty.
The current model is quite similar in spirit to, and
somewhat inspired by, that proposed by Berry and
Berry (2004). They also assume that drug adverse
reactions are classified into similar medical group-
ings in order to use a shrinkage model to allow bor-
rowing strength across similar medical events. They
focus on treatment/comparator odds ratios only and
do not consider covariates or the use of logistic re-
gression. They also define a more complex model
having many more variance components than the
one proposed here.
One might ask the question of why estimate co-
variate effects at all, since in a randomized study
the covariates should all be nearly orthogonal to the
treatment variable? The rationale in MBLR is not so
much to adjust for potential biases in the treatment
main effect, but to be able to include treatment-
by-covariate interactions in order to detect possibly
vulnerable subgroups that might react differently to
the treatment. When G is large (many covariate cat-
egories) it will often be difficult to estimate so many
parameters unless all the issues being modeled oc-
cur frequently. The multiple comparisons involved
make any search for vulnerable subgroups difficult
and subject to false alarms, especially for sparse
events. This makes the use of Bayesian shrinkage of
the interaction terms in (6) especially valuable: it ne-
gotiates the bias-variance trade-off among multiple
event rates having possibly very different sampling
variances. Without this smoothing effect, estimates
of interactions affecting rare events will be so vari-
able as to be useless, which is why the RLR method
is defined to estimate only main effects.
The importance of avoiding undue rejection of the
null hypothesis in the presence of multiple post-hoc
comparisons is central to being properly conserva-
tive when evaluating treatment efficacy. There is
a question as to how much this conservatism should
extend to exploratory analyses of safety issues. For
example, the prior specification (6) shrinks the inter-
action prior means Bg toward 0, whereas the main
effect prior means Ag and B0 are not shrunk to-
ward 0. We prefer to maintain maximum sensitivity
to safety main effects, while accepting that true in-
teraction effects are less likely and need more false
alarm protection. We also encourage parallel com-
putation of the minimal-shrinkage regularized LR
estimates discussed above, so that the analyst can
perform an easy comparison and sensitivity analysis
of the effects of shrinkage.
The prior distributions in equations (3)–(6) are all
assumed to be normal distributions. Many Bayesian
researchers have pointed out that since normal dis-
tributions generate few outliers, outliers may be cor-
respondingly suppressed under this assumption.
Commonly suggested alternative prior distributions
are the double exponential and Student’s t, which
tend to shrink outliers less. The double exponential
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Issue Treatment events Comparator events 95% C.I. for Odds Ratio
Anuria 8 0 (1.0 , 295.4)
Dry mouth 308 65 (3.9 , 6.7)
Hyperkalaemia 218 162 (1.1 , 1.7)
Micturition urgency 13 3 (1.2 , 12.6)
Nocturia 19 7 (1.1 , 6.1)
Pollakiuria 193 34 (4.1 , 8.5)
Polydipsia 49 4 (4.2 , 29.3)
Polyuria 100 17 (3.5 , 9.8)
Thirst 543 66 (7.5 , 12.6)
Urine output increased 13 1 (1.7 , 48.8)
Subject counts: Treatment = 3110 Comparator = 2642
Display 1. Statistics for ten issues related to dehydration/renal function for the pooled studies.
(“lasso”) prior has nonstandard theoretical proper-
ties that make computation of standard errors of co-
efficients problematical, and so have been ruled out
for this application. Alternative distributions like
Student’s t are difficult to handle computationally in
our complex situation where there are hundreds of
coefficients and multiple variance components. The
normal model that we use has a concave log pos-
terior density function and the iterative estimation
algorithm is guaranteed to converge.
There is a similar computational feasibility ra-
tionale for using the discrete approximation to the
distribution of prior standard deviations. It is more
common in the recent Bayesian literature to use
Gibbs sampling or another Markov chain Monte
Carlo (MCMC) method to estimate the posterior
distributions of all parameters. Two reasons for pre-
ferring to avoid such methods are as follows: first,
we want to allow scientists without much statisti-
cal sophistication, much less experience with fancy
Bayesian computational methods, to use MBLR and
these users would have trouble assessing convergence
of such high-dimensional MCMC runs. Second, these
users might also be uncomfortable with the fact that
repeating an analysis on the same data typically
leads to slightly, but noticeably, different answers.
The method for handling the variance component
estimation outlined above provides computationally
and statistically reliable answers within a feasible
computational burden. As described above, there
are three roughly equally expensive stages in the
model fitting computations: the two preparatory
stages of finding the maximum of the posterior dis-
tribution and then evaluating it on an initial grid to
find scale parameters in each direction, and the last
stage of evaluating the model on the final grid to ap-
proximate the posterior distribution of the variance
components.
5. EXAMPLE ANALYSIS
Data Description
The data used for the example analyses are from
a pool of eight studies, kindly contributed by an
anonymous partner. Four of the studies were for one
indication and four were for a second indication.
There were a total of 5752 subjects in the pooled
studies, 3110 in the Treatment arm and 2642 in the
Comparator arm.
Display 1 shows statistics from these studies for
a set of ten issues related to dehydration and/or re-
nal function. All ten issues show up with greater
frequency in the treatment arm than in the com-
parator. The final two columns are the endpoints of
95% confidence intervals for the odds ratios compar-
ing treatment and comparator groups in the pooled
data, computed using a normal approximation for
the log (odds ratio) after adding 0.5 to every cell
of each 2 × 2 table. It is clear that many of these
issues are associated with treatment, and we wish
to investigate the commonality of these medically
related issues, as well as the possibility that certain
subgroups of subjects may be more or less affected
by these associations.
Display 2 shows the four covariates selected as
grouping variables for this analysis: Gender, Study
ID, Renal History and Age. Recall that of the 8 stud-
ies being pooled, there were 4 studies for each of two
potential indications for the drug. The Study ID val-
ues of A1–A4 and B1–B4 distinguish the studies for
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Treatment Comparator
Gender = F 908 685
Gender = M 2202 1957
Study = A1 246 84
Study = A2 120 120
Study = A3 239 80
Study = A4 191 63
Study = B1 102 103
Study = B2 17 11
Study = B3 123 120
Study = B4 2072 2061
Renal history = Y 190 191
Renal history = N 2920 2451
Age = 50 or under 382 348
Age = 51 to 65 1089 902
Age = 66 to 75 948 820
Age = Over 75 691 572
All patients 3110 2642
Display 2. Distribution of subjects by covariates and treat-
ment arm.
indication A and indication B. The Renal History
variable distinguishes those subjects whose medical
history (before randomization) includes one or more
renal problems. As can be seen from Display 2, there
are many more male than female subjects, and the
age range 51 to 75 predominates. Three of the stud-
ies for indication A had about a 3:1 split of Treat-
ment to Comparator subject counts, while the other
five studies are more equally split. Study B2 had
only 28 subjects total, while Study B4 had 4133 sub-
jects, over two-thirds of the total in the pool. Only
about 7% of the subjects had a previous history of
renal problems.
Display 1 shows that five of the ten issues af-
fected fewer than 10 Comparator-group subjects,
whereas there are 16 separate covariate groups in
Display 2. This makes it unlikely that those rare is-
sues would occur in every treatment–covariate com-
bination, which is necessary for convergence of a stan-
dard LR where the model includes all treatment–
covariate interaction terms. In fact, only 3 of the
10 issues satisfy this condition, confirming the ne-
cessity of some special technique such as MBLR
to try to estimate treatment-by-covariate interac-
tions, and, in fact, even a main-effects only model
would not be estimable by standard logistic regres-
sion applied to the rarer of these response issues,
making the regularized LR necessary for this exam-
ple.
Posterior Distributions for Prior Standard
Deviations
This example has K = 10, J = 4 and G= 16, with
the total number of parameters (elements of θ) to
estimate beingM = 2(G+1)(K+1)−1 = 373, with
M∗ = 285 degrees of freedom. Display 3 shows var-
ious results as a function of the four prior stan-
dard deviations. The top row 0 describes the reg-
ularized LR case where σA = 5, σ0 = 5, σB = 0.001,
τ = 0.001. The rows labeled 1–33 in Display 3 show
results for the final grid used to approximate the
posterior distribution of φ. The row 1 values are the
maximum posterior estimates (transformed from the
scale of λ to that of φ) estimated by the final re-
sponse surface fit described above. Rows 2–33 show
the remaining values of the final stage grid. In this
example, all stages of the estimation required a to-
tal of about 400 iterations through the data, that
is, about 400 evaluations of (8) and its first and sec-
ond derivatives with respect to M∗ = 285 parame-
ters.
The rightmost column in Display 3, headed “PROB,”
shows the values of 100pi%, as defined by (16). As
discussed above, these probabilities have been ad-
justed so that the discrete distribution of λ matches
the means and variances of the continuous distribu-
tion of λ as estimated by the response surface fit to
the values of log g.
The bottom two rows of Display 3 show the pos-
terior mean and standard deviations of the compo-
nents of φ using this 33-point discrete approxima-
tion. It can be seen that the values are approxi-
mately (σA = 0.34, σ0 = 0.76, σB = 0.15, τ = 0.20).
The value in the row marked “Mean” and the col-
umn marked “PROB” is computed as
∑
s pi
2
s = 0.0639,
which is a measure of the dispersion of the probabil-
ities pis. The smaller it is, the more spread out are
the probabilities among the 33 grid points. Large
values of
∑
s pi
2
s , say, values above 0.2, would imply
that the scale or location of the grid might be poorly
chosen, so that only a few points on the grid are very
probable.
Comparison of MBLR and RLR Estimates of
Treatment Effects
Display 4 shows estimation results for the treat-
ment main effects for each of the two methods and
for each response event and for the prior mean of
all responses. The prior mean odds ratio is defined
as exp(B0), whereas the treatment odds ratio for
the kth response is exp(β0k). For each combination
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σA σ0 σB τ PROB
0 5.000 5.000 0.001 0.001 0.00%
1 0.327 0.688 0.161 0.196 15.90%
2 0.276 0.505 0.110 0.312 1.87%
3 0.276 0.505 0.232 0.118 3.02%
4 0.276 0.879 0.110 0.118 2.71%
5 0.276 0.879 0.232 0.312 4.32%
6 0.384 0.505 0.110 0.118 4.25%
7 0.384 0.505 0.232 0.312 1.83%
8 0.384 0.879 0.110 0.312 5.01%
9 0.384 0.879 0.232 0.118 1.75%
10 0.252 0.423 0.090 0.091 0.14%
11 0.252 0.423 0.276 0.387 0.42%
12 0.252 0.969 0.090 0.387 0.88%
13 0.252 0.969 0.276 0.091 0.83%
14 0.416 0.423 0.090 0.387 0.51%
15 0.416 0.423 0.276 0.091 0.10%
16 0.416 0.969 0.090 0.091 5.40%
17 0.416 0.969 0.276 0.387 0.13%
18 0.231 0.688 0.161 0.196 1.86%
19 0.448 0.688 0.161 0.196 2.13%
20 0.327 0.350 0.161 0.196 1.37%
21 0.327 1.053 0.161 0.196 6.96%
22 0.327 0.688 0.074 0.196 8.12%
23 0.327 0.688 0.327 0.196 0.75%
24 0.327 0.688 0.161 0.070 5.80%
25 0.327 0.688 0.161 0.473 3.21%
26 0.192 0.688 0.161 0.196 0.87%
27 0.518 0.688 0.161 0.196 2.43%
28 0.327 0.232 0.161 0.196 0.02%
29 0.327 1.196 0.161 0.196 4.69%
30 0.327 0.688 0.049 0.196 5.54%
31 0.327 0.688 0.447 0.196 0.00%
32 0.327 0.688 0.161 0.041 6.18%
33 0.327 0.688 0.161 0.670 1.01%
Mean 0.336 0.756 0.146 0.196 6.39%
St.Dev. 0.053 0.183 0.053 0.105
Display 3. Calculation summary for the final grid of prior standard deviations.
the odds ratio and its approximate 90% confidence
(credible) interval are shown, based on (18). Com-
paring the MBLR to the RLR estimates, we see that
the MBLR estimates are pulled away from the RLR
estimates and “shrunk” toward the MBLR prior
mean, which represents the average or typical odds
ratio across response issues. The degree of shrinkage
is greatest for the highest-variance RLR estimates,
corresponding to the rare issues such as Anuria and
Urine output increased. For these two issues, al-
though the MBLR odds ratio estimate is smaller
than the corresponding RLR odds ratio, but so are
their posterior variances, so that the lower bounds
of the MBLR intervals are greater, providing greater
statistical significance from the null hypothesis of
OR = 1. Even though all 8 occurrences of Anuria
were in the treatment arm, the treatment effect does
not show up as significant with the multiple-predictor
RLR model—the MBLR estimate of the effect on
Anuria seems more reasonable.
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Display 4. Estimates of main effect of treatment by method and response variable.
Inspection of Display 4 shows that not all of the
MBLR confidence intervals are narrower than the
corresponding RLR interval. The reverse is true for
the more frequent responses such as Hyperkalaemia
and Thirst. In these cases, the MBLR estimates do
not benefit much from the relatively weak prior dis-
tribution, and their posterior variances are adversely
impacted by the uncertainty in the variance compo-
nent estimation as well as the need to estimate all of
the interaction parameters, which are assumed away
by the RLR model.
MBLR Estimates of Prior Means
Display 5 graphs the MBLR estimates of the (ex-
ponentiated) prior means {Ag,B0,Bg}, with their
90% CIs. These are interpreted as effects for a “typ-
ical” response variable. Remembering that coeffi-
cients for categories of each covariate must sum to 0,
the corresponding odds ratios must average to 1
when plotted on a log scale. The middle interval
shows the main effect of treatment, the intervals
above show covariate main effects, and the intervals
below show treatment interactions. As also shown in
Display 4, the treatment effect prior mean is about
4.4 on the odds ratio scale, with 90% limits of (2.7,
7.1). The main effects of covariate estimates, shown
above the treatment line, can be thought of as the
effects of covariate categories within the compara-
tor arm, and as centers of shrinkage across the re-
sponses. Thus, the rates of these events in the com-
parator arm are somewhat less for Age:50 and un-
der and for Renal History:N. Also, Study:A2 had
a particularly high event rate, while Study:B4 had
a particularly low event rate. But none of these dif-
ferences in groups based on covariates are as large
as the treatment effect.
The lower set of estimates in Display 5 portray the
treatment–covariate interactions. As can be seen,
these effects are smaller than the main covariate ef-
fects and much smaller than the main treatment ef-
fect. The treatment effect estimates within the four
studies for Indication A are all larger than the four
estimates for the Indication B studies, but the uncer-
tainty intervals all overlap considerably. Although
this does not rule out larger interaction effects for
some of the response variables, the fact that σA, is
about 0.3 and both σB , and τ are each less than
0.2 means that such effects for individual responses
are also likely to be fairly small. Since σ0 is about
0.76, there is more room for variation in treatment
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Display 5. Estimates of PRIOR MEAN from MBLR.
main effect among the responses, as we also saw in
Display 4, where the Treatment odds ratios ranged
from 1.3 for Hyperkalaemia to 7.4 for Polydipsia.
The prior means of the treatment by covariate
interactions (the bottom 16 intervals of Display 5)
have especially small posterior means, as might be
expected given that they have been shrunk toward 0
because of the small value of τ , with posterior mean
= 0.196 in Display 3. Another way of saying this is
that the estimates of Bg were so small compared to
their sampling variances that only a small value of τ
is compatible with these results and the assumption
of (6).
The estimates of prior means under the regular-
ized LRmodel are less interesting. Assuming that σA
and σ0 are large implies that Ag and B0 cannot be
estimated well and will thus have wide confidence
intervals, and of course assuming no interactions
means that the Bg = 0 for g > 0.
Breakdown of Estimates by Study for Issue
Pollakiuria
Display 6 shows the MBLR 90% intervals for odds
ratios relating to the Study ID covariate and the is-
sue Pollakiuria (very frequent daytime urination).
The 2× 2 table information in Display 1 shows that
this was highly associated with treatment (193:34
split by treatment:comparator). Our discussion fo-
cuses on whether and how the results differ by the
studies being pooled, and what summary conclu-
sions are justified across studies. The goal is sim-
ilar to meta-analysis, except that we have complete
data from each study and so can adjust for more
potentially biasing between-study differences.
The top eight intervals in Display 6 show the Study
main effects, corresponding to relative differences
among the comparator arm odds of reporting Pol-
lakiura within the studies. These differential esti-
mates are adjusted for the other covariates Age,
Gender and RenalHistory. There are relatively large
and significant study effects, especially between
Study A2 and Study B4, where the estimated odds
ratio is over 8 (2.8 versus 0.34 on the horizontal
axis), with relatively narrow 90% intervals.
The next set of eight intervals shows the Treat-
ment by Study interaction estimates. Although the
differences are not as large as in the comparator
arms, the pattern is similar, in that the studies that
had a large base rate of Pollakiuria tended to have
larger increases in adjusted Pollakiura rates. The
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Display 6. MBLR estimates of odds ratios relating to the Study covariate for the response Pollakiuria.
three studies having the largest treatment effects
(A1, A2, A4) are all based on Indication A. These
estimates are somewhat hard to interpret, being ra-
tios of odds ratio estimates. The lower set of inter-
vals return to the simple odds ratio scale by adding
(on the log scale) the interaction estimates to the
main effect of treatment. The very bottom interval
shows the 90% interval for the treatment main ef-
fect, and the central points for the eight intervals
above it average to the center point at the bottom.
These last 9 intervals in Display 6 are reminis-
cent of the way a meta-analysis is often presented in
a “ladder plot,” with estimates of effect for each study,
and followed by a combined treatment estimate at
the bottom. However, there are certain differences
due to the more complex MBLR model. First, as
mentioned above, these estimates have been adjusted
for differential covariate distributions across stud-
ies. Second, the Pollakiuria estimates here have been
shrunk toward the prior mean estimates of the odds
ratios involving all responses. Third, the shrinkage of
interaction estimates toward 0, governed by τ in (6),
is similar to the shrinkage toward a common mean
effect that occurs in a random effects meta-analysis.
Fourth, the weight that each study contributes to
the overall estimate is governed by a more complex
formula than in either the standard fixed or ran-
dom effects meta-analyses. However, it does share
with the random effects methodology the fact that
relative weights are much attenuated compared to
relative sample sizes. Finally, this more complex cal-
culation means that the single-study treatment es-
timates in the above MBLR graph do not preserve
the between-study differences, as might be shown in
a standard meta-analysis presentation.
The response Pollakiuria was chosen as the exam-
ple for Display 6 because that issue showed a greater
Treatment-by-Study effect than other issues: for ex-
ample, in Display 6 the Trt*Study:A1 effect is 1.33,
while the Trt*Study:B4 effect is 0.79, for a ratio of
1.68, and the two 90% intervals barely overlap. Is
this post-hoc selection legitimate? Clearly, this way
of finding “interesting” results is biased in many
standard settings. However, the Bayesian shrinkage
methodology tends to offset such biases, as will be
seen in the simulation results to follow.
6. SIMULATION STUDY OF MBLR AND RLR
The statistical properties of MBLR are studied
using a simulation of the model that MBLR as-
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sumes. The purpose is to compare the accuracy of
the MBLR results with that of the RLR results in
the context of a situation like that in the example
of Section 5, where there are rare events and sparse
data. The simulation emulates that example in the
sense that the distribution of subject covariates and
treatment assignment matches the data in Section 5
exactly. Also, the list of response issues is the same
and the baseline probabilities (as measured by the
intercept term in the logistic regressions) of each re-
sponse in the simulation are similar to that in the
data of Section 5. The protocol for each simulation
involves the following steps:
1. Set the K intercept term values α0k, one for
each of the responses.
2. Set the G+1 prior means A1,A2, . . . ,AG,B0.
3. Set the four prior standard deviations φ= (σA,
σ0, σB, τ).
4. Repeat steps (5 through 12) NSIM times:
5. Draw {αgk} from N(Ag, σ
2
A), g = 1, . . . ,G;
k = 1, . . . ,K.
(Note: all random variable generation is
performed using built-in R functions. Also,
constraints that αgk must sum to 0 as g
varies over the categories of each single co-
variate are enforced by subtracting means
over the corresponding covariate from the
originally drawn αgk. An analogous proce-
dure is used in steps 7 and 8.)
6. Draw {β0k} from N(B0, σ
2
0), k = 1, . . . ,K.
7. Draw {Bg} from N(0, τ
2), g = 1, . . . ,G.
8. Draw {βgk} from N(Bg, σ
2
B), g = 1, . . . ,G;
k = 1, . . . ,K.
9. For each set of ni subjects having the same
covariate values and treatment assignment,
compute Zik and Pik using (1) and (2), i=
1, . . . ,m; k = 1, . . . ,K.
10. Draw {Nik} from binomial (ni, Pik), i =
1, . . . ,m; k = 1, . . . ,K.
11. Fit both the MBLR and the RLR model to
the counts {Nik}.
12. Update cumulative summaries of estimation
results for each simulation as described be-
low.
13. Create reports summarizing the estimation ac-
curacy of the two methods regarding all param-
eters.
Simulation Summary Statistics
There areM = 2(G+1)(K+1)−1 parameters be-
ing estimated and two estimation methods: MBLR
and RLR, so the total number of estimators being
evaluated is R = 2M . For simulation s (s = 1, . . . ,
NSIM) and for estimate r (r = 1, . . . ,R), let:
θrs = true value of parameter r for simulation s,
as defined by steps 1, 2, 5, 6, 7 and 8,
qrs = estimated value (posterior mean) of param-
eter r for simulation s,
sers = estimated SE (posterior standard devia-
tion) for parameter estimate r for simulation s,
BIASr =
∑
s(qrs− θrs)/NSIM [average estimation
error],
RMSEr =
√
(
∑
s(qrs − θrs)
2/NSIM) [square root
of mean squared estimation error],
Z2r = (
∑
s(qrs−θrs)
2/se2rs)/NSIM [average squared
standardized estimation error],
CI.05r = (# times qrs + 1.645sers < θrs)/NSIM
[proportion of times 90% CI is too low],
CI.95r = (# times qrs − 1.645sers > θrs)/NSIM
[proportion of times 90% CI is too high].
These summary statistics focus on the estimation
accuracy of qrs and also on the calibration accuracy
of sers. We want BIAS and RMSE to be as close to
0 as possible, we want Z2 to be near 1, and we want
CI.05 and CI.95 to be near 0.05. The R estimates
can be grouped by the two methods, the (K + 1)
responses (counting PRIOR MEAN as a general-
ized response) and the 2G + 2 different term defi-
nitions. The term definitions fall into three general
term types:
COV = {Ag, αgk},
TREAT= {B0, β0k},
TRT∗COV= {Bg, βgk}.
We can summarize the simulation of the R es-
timates by averaging the six accuracy summaries
listed above over groups defined by method, response
and/or term type.
Finally, for the MBLR, we can summarize the pos-
terior means and standard deviations of the four es-
timated prior standard deviations.
Simulation Design
The simulations are designed to compare varia-
tions in three design factors, each at two levels, so
that 8 separate simulations were performed, with
each simulation having NSIM = 250 replications, and
so that a simple comparison of the two levels of each
factor will be based on 1000 replications at each
level. The three design factors correspond to two
different choices at each of the first three steps in
the simulation protocol given above:
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Response Intercept Base.Prob
1. Hyperkalaemia −2.906 0.0547
2. Thirst −3.333 0.0357
3. Dry mouth −3.429 0.0324
4. Pollakiuria −3.645 0.0261
5. Polyuria −4.787 0.0083
6. Nocturia −5.646 0.0035
7. Polydipsia −5.819 0.0030
8. Micturition urgency −6.618 0.0013
9. Urine output increased −6.972 0.0009
10. Anuria −7.722 0.0004
Display 7. Estimated values of intercept terms α0k that
are used in the simulations. When K = 5, only the first 5
responses in the display are used. The baseline probabilities
are defined as exp(α0k), which range from 0.055 for Hyper-
kalaemia to 0.00044 for Anuria.
Factor 1, Level 1: Frequent responses only (most fre-
quent 5 in the example data).
Factor 1, Level 2: Both frequent and rare responses
(all 10 issues in the example data).
The K = 10 situation uses the same 10 issues
as in the example of Section 5, with the values
of the intercept terms α0k set equal to the esti-
mated values from the real data, shown in Dis-
play 7. The baseline probabilities are defined as
exp(α0k), also shown, which range from 0.055
for Hyperkalaemia to 0.00044 for Anuria. When
K = 5, the most frequent 5 response issues are
used, as shown in rows 1–5 of Display 7.
Factor 2, Level 1: Average of main effects = 0 (Ag =
0 for all g, B0 = 0).
Factor 2, Level 2: Prior Means of main effects rela-
tively large nonzero values.
For Level 2, the values of A1, . . . ,AG,B0 are set
to two times the values estimated in the analy-
sis of the actual data. Display 8 shows the co-
efficient values as estimated and as used in the
simulations.
Factor 3, Level 1: σA = 0.4, σ0 = 0.6, σB = 0.2, τ =
0.2 (Small PSDs).
Factor 3, Level 2: σA = 1.0, σ0 = 1.2, σB = 0.8, τ =
0.8 (Large PSDs).
The Level 1 values of prior standard deviations
are similar to those estimated from the example
data, while the Level 2 values are significantly
larger.
All simulations create 5752 subjects having the
same joint distribution of covariates and treatment
allocations as the actual data and as summarized
Term Estimated Level 1 Level 2
Gender: F 0.028 0 0.056
Gender: M −0.028 0 −0.056
Study: A1 0.094 0 0.188
Study: A2 0.529 0 1.058
Study: A3 −0.325 0 −0.65
Study: A4 0.33 0 0.66
Study: B1 0.293 0 0.586
Study: B2 −0.232 0 −0.464
Study: B3 −0.273 0 −0.546
Study: B4 −0.417 0 −0.834
RenalHistory: N −0.187 0 −0.374
RenalHistory: Y 0.187 0 0.374
Age: 50 and under −0.251 0 −0.502
Age: 51–65 0.109 0 0.218
Age: 66–75 0.239 0 0.478
Age: over 75 −0.097 0 −0.194
Treatment 1.484 0 2.968
Display 8. Prior means for the main effects, as estimated
by MBLR from the real data, and as varied in the simulations,
either all zeros (Level 1), or set to twice the estimated values
(Level 2).
in Display 2. Thus, G = 16 and M = 203, R = 566
whenK = 5, whileM = 373, R= 1066 whenK = 10.
Simulation Results
Display 9 shows summaries of the distributions
of (square roots of) variance component estimates,
which are denoted PSDs for prior standard devia-
tions in the model equations (3)–(6). Since there are
4 separate PSDs in the model, and the simulations
are run at two sets of PSDs, the scales of all the
PSDs in Display 9 have been normalized by divid-
ing each estimated PSD and each estimated sam-
pling standard deviation by the true PSD used in
the corresponding simulation. Thus, a value of 1 for
an average estimated PSD in Display 9 is interpreted
as an unbiased estimate, and a value of 0.1 for the
standard deviation of the sampling distribution of
a PSD in Display 9 is interpreted as a coefficient of
variation of 10%.
Display 9 has 8 columns and 7 rows. There are
4 pairs of columns, corresponding to the sampling
means and standard deviations of the estimates of
each of the four PSDs in the model. The 7 rows of
Display 9 correspond to different subsets of the 2000
simulations. Row 1 shows averages over all simula-
tions, whereas the other rows show averages over
a subset of 1000 simulations corresponding to the
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σA SDσA σ0 SDσ0 σB SDσB τ SDτ
All MBLR simulations 1.035 0.130 1.005 0.271 0.988 0.236 1.088 0.368
Responses: Frequent 1.044 0.144 1.004 0.283 1.004 0.253 1.073 0.373
Responses: Freq + Rare 1.026 0.116 1.007 0.260 0.971 0.219 1.102 0.363
Mean effects: Zero 1.034 0.133 1.005 0.276 1.000 0.245 1.091 0.376
Mean effects: Large 1.035 0.126 1.006 0.267 0.975 0.227 1.084 0.360
Prior SDs: Small 1.037 0.153 1.131 0.353 0.954 0.340 1.136 0.476
Prior SDs: Large 1.033 0.106 0.879 0.190 1.022 0.132 1.039 0.259
Display 9. Summary of estimation of prior standard deviations (PSD) in the MBLR simulations. All estimated PSDs are
divided by the true PSD to put their sampling distributions on a common scale. The row “All Simulations” shows means
and standard deviations of normalized estimates across all 2000 simulations. Other rows show results for subsets of 1000
simulations broken down by the two levels of each of the three design factors in the experiment. See text for explanation of the
design factors and their levels.
levels of each of the factors in the experimental de-
sign. For example, consider the columns labeled σ0
and SDσ0 in Display 9. In row 1, 1.005 implies that
overall the mean of estimates of the Treatment PSD
are within 0.5% of the true value, and the next value
of SDσ0 = 0.271 implies that individual estimates
are typically about 27% off the true value. Of course
that value is principally reflective of the sample size
and the experimental design of the clinical studies.
All simulations used the same clinical study setups,
but there was variation according to the three fac-
tors in the simulation. Going down the rows in these
same two columns, we see that estimates of σ0 had
almost exactly the same means and standard devia-
tions whether all ten responses were being simulated
or whether just the most frequent five responses
were simulated. Similarly, the next two rows show
that there was virtually no difference in the sam-
pling means and standard deviations of σ0 between
the situation where the average effects are about 0
versus relatively large effects. However, the final two
rows of the Display show that when all four PSDs are
small (σA = 0.4, σ0 = 0.6, σB = 0.2, τ = 0.2) the es-
timate of σ0 is biased upward about 13%, and when
all four PSDs are large (σA = 1.0, σ0 = 1.2, σB = 0.8,
τ = 0.8) it is biased downward by about the same
percentage. The direction of the biases implies that
estimates tend to be somewhat more central with re-
spect to the restricted range imposed (0< σ0 < 1.5)
than the true value, thus moderating the estimates.
The coefficient of variation of σ0 is about 35% in the
former case and about 19% in the latter case. This
corresponds to roughly the same standard deviation
of the estimate of σ0 whether σ0 is 0.6 or 1.2.
This effect only shows up with respect to σ0; the
other columns in Display 9 show that mean esti-
mates of σA, σB and τ are relatively unaffected by
any of the three factors in the simulation, especial-
ly σA and σB . Consideration of degrees of freedom
may explain this—these two variance components
have (G − J)(K − 1) degrees of freedom, whereas
σ0 has K − 1 df and τ has G− J df, so one might
expect them to be harder to estimate (although the
definition of degrees of freedom is somewhat fuzzy
in this nonlinear Bayesian setting). Estimates of τ
seem to be most variable percentagewise, with co-
efficient of variation in the 30–40 percent range. In
all cases the coefficient of variation is larger for the
smaller true PSDs. The standard deviation of esti-
mation decreases when the true PSD decreases, but
not fully proportionally.
However, remember that the goal of the analysis is
not to estimate the variance components per se, but
to use them to define a model that can better esti-
mate the logistic coefficients by adjusting to global
patterns in the data across responses and predic-
tor categories. Each individual estimation does not
assume that the PSDs are exactly equal to their pos-
terior mean, but rather the estimation involves an
integration across the posterior distribution of the
PSDs. In that respect, it is interesting to examine
the posterior standard deviations of the PSDs. They
have not been included in Display 9 in order to save
space, but in fact the average of the posterior stan-
dard deviations across simulations was remarkably
similar to the sampling standard deviations of the
posterior means of each PSD. They typically differed
by only 10% or so for each of the 8 sets of 250 simula-
tions. Thus, our model expects that the PSDs will be
hard to estimate and works within that uncertainty.
Estimation of Logistic Coefficients
Display 10 summarizes the simulation distribu-
tions of the various logistic regression coefficients.
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(a) Treatment effect prior mean B0 Treatment effect for responses β0k
RMSE Z2 CI.05 CI.95 RMSE Z2 CI.05 CI.95
All RLR simulations 0.719 0.192 0.000 0.003 1.066 26.026 0.108 0.354
All MBLR simulations 0.383 1.167 0.056 0.070 0.466 1.248 0.061 0.074
Responses: Frequent 0.424 1.235 0.068 0.067 0.314 1.200 0.059 0.073
Responses: Rare 0.343 1.099 0.044 0.073 0.619 1.297 0.063 0.075
Mean effects: Zero 0.386 1.163 0.046 0.076 0.491 1.284 0.052 0.090
Mean effects: Large 0.381 1.170 0.066 0.064 0.442 1.212 0.070 0.058
Prior SDs: Small 0.286 1.023 0.043 0.062 0.375 1.217 0.058 0.073
Prior SDs: Large 0.481 1.310 0.069 0.078 0.557 1.280 0.064 0.076
(b) Covariate effect prior means Ag Covariate effect for responses αgk
RMSE Z2 CI.05 CI.95 RMSE Z2 CI.05 CI.95
All RLR simulations 0.490 0.105 0.000 0.000 0.819 11.662 0.166 0.190
All MBLR simulations 0.297 0.972 0.044 0.052 0.373 1.041 0.049 0.057
Responses: Frequent 0.323 0.959 0.043 0.052 0.280 1.041 0.049 0.056
Responses: Rare 0.272 0.986 0.045 0.052 0.466 1.042 0.049 0.057
Mean effects: Zero 0.300 0.959 0.042 0.051 0.388 1.026 0.047 0.056
Mean effects: Large 0.295 0.986 0.046 0.053 0.358 1.056 0.051 0.057
Prior SDs: Small 0.205 0.990 0.044 0.055 0.283 1.048 0.050 0.057
Prior SDs: Large 0.390 0.954 0.043 0.049 0.463 1.034 0.048 0.057
(c) Interaction effect prior means Bg Interaction effect for responses βgk
RMSE Z2 CI.05 CI.95 RMSE Z2 CI.05 CI.95
All MBLR simulations 0.347 3.189 0.151 0.144 0.346 1.116 0.059 0.057
Responses: Frequent 0.353 2.940 0.144 0.141 0.292 1.110 0.059 0.056
Responses: Rare 0.340 3.439 0.159 0.147 0.399 1.122 0.059 0.057
Mean effects: Zero 0.347 3.114 0.150 0.140 0.360 1.120 0.060 0.057
Mean effects: Large 0.346 3.265 0.152 0.148 0.331 1.112 0.059 0.056
Prior SDs: Small 0.171 2.489 0.130 0.122 0.203 1.174 0.062 0.061
Prior SDs: Large 0.522 3.890 0.173 0.166 0.488 1.058 0.056 0.053
Display 10. Summary of estimated logistic coefficient distributions within the simulations. Separate subtables for (a) treat-
ment effects B0 and β0k , (b) covariate main effects Ag and αgk, (c) treatment-by-covariate interactions Bg and βgk
(g = 1, . . . ,G). See text for explanation of the summary statistics.
Part (a) of Display 10 focuses on the main effect of
Treatment. The first two rows of Display 10(a) com-
pare the Treatment effect accuracy of the RLR esti-
mates to that of the MBLR estimates. The first four
columns refer to the estimation of the prior mean co-
efficient, B0, what might be called the “all response
summary,” while the last four columns refer to the
estimation of coefficients, β0k, for the individual re-
sponses. Across all 2000 simulations, the RMSE for
RLR is almost double that of MBLR for estima-
tion of B0, and more than double, on average, for
estimating the β0k. Since statistical efficiency is typ-
ically inversely proportional to the square of RMSE,
this implies that MBLR is about 4 times as efficient
as RLR at estimating treatment/comparator odds
ratios in this setting.
The statistic Z2 is designed to measure the cal-
ibration of the posterior standard deviations com-
puted by a method to the actual sampling distribu-
tion, where Z2 = 1 implies perfect calibration. When
Z2 ≫ 1, the claimed standard errors of coefficients
are too optimistic (too small), and the reverse is
true when Z2≪ 1. The values of Z2 provide similar
information to the counts of times confidence inter-
vals fail to enclose the true values of coefficients.
When Z2 is too large and putative standard errors
are too small, the too-short confidence intervals will
miss the true values more than the nominal percent
of times, and conversely. Looking at the first two
rows of Display 10(a), we see that RLR is poorly
calibrated in this sense. Computed standard errors
are too large for the all-response summary and too
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small for the individual response treatment effects.
As a result, supposedly 90% confidence intervals had
99.7% coverage for the all-response summaries and
only 53.8% coverage for individual response treat-
ment effects. In contrast, the MBLR estimates are
much better calibrated, with Z2 about 1.2 and nomi-
nally 90% intervals having coverage probabilities av-
eraging about 87%.
The remaining rows of Display 10(a) show the be-
havior of the MBLR estimation for subsets of simu-
lations defined by the three two-level factors. Rows 3
and 4 compare results for simulations with the 5
more frequent responses to those for the 5 less fre-
quent responses. In the latter case, although the
runs generated all 10 responses and all 10 were used
in the analysis, the results in the row labeled “Re-
sponses: Rare” are based only on accuracy statistics
for the 5 least frequent responses, in order to bet-
ter isolate the estimation ability of MBLR for rare
events. We see that in fact the RMSE, Z2, and 90%
interval coverage probabilities are roughly the same
for the rare and frequent events. (Of course, we as-
sume that a run with only the five rare events would
lead to much more variable estimation—it is the
ability of the Bayesian algorithm to detect and mea-
sure similarities between frequent and rare events,
and to “borrow strength” appropriately, that allows
such accuracy.) The next two rows of Display 10(a)
show that whether the true prior means are 0 or
not makes no difference in the estimation properties.
The final two rows of Display 10(a) show that esti-
mation is significantly more accurate when PSDs are
small than when they are large, which make sense,
because small PSDs imply more commonality across
the responses, and thus more opportunity to borrow
strength and increase estimation accuracy. But even
with the larger set of PSDs, MBLR quite outper-
forms RLR.
Display 10(b) shows the corresponding results for
the estimation of covariate main effects. For this ex-
ample, the estimation of Ag and αgk seems to be
more accurate, using either RLR or MBLR, on av-
erage for the 16 covariate effects (indexed by g) than
it was for the single main effect of treatment. How-
ever, the advantage of MBLR over RLR is about
the same, both in terms of RMSE and in terms of
standard error calibration as measured by Z2 and
the coverage probabilities of nominal 90% intervals.
Display 10(c) shows the simulation accuracy of
estimation of covariate–treatment interaction coeffi-
cients. Since the RLR model does not estimate inter-
actions, only MBLR results are presented. Looking
first at the right-hand set of four columns in Dis-
play 10(c) that refer to estimation of the βgk, all
four accuracy measures seem to mimic the values
in Display 10(b)—it appears that MBLR can es-
timate individual covariate–treatment interactions
as accurately as the main effects of covariates. Now
looking at the first four columns of Display 10(c),
where the Bg are being estimated, the entire col-
umn of RMSE values are about the same as in Dis-
plays 10(a) and 10(b), so the posterior mean esti-
mates of the Bg are about as accurate as those of B0
and of Ag. However, it seems that the posterior stan-
dard deviations of the Bg are too optimistic, since
the values of Z2 are about 3 times too large, and
the error rate of the corresponding nominal 90% in-
tervals is about 30% instead of 10%. This result is
puzzling and awaits further investigation.
Bayesian Shrinkage Estimates are Resistant to
the Multiple Comparisons Fallacy
Display 11 shows the remarkable power of Bayesian
shrinkage estimates to avoid bias even in the pres-
ence of post-hoc selection of the most significant of
many estimates. For each simulation, the task is
True Int. Bias RMSE Z2 CI.05 CI.95
All MBLR simulations 0.976 0.004 0.173 1.314 0.070 0.070
Responses: Frequent 0.985 0.007 0.179 1.346 0.078 0.077
Responses: Freq +Rare 0.968 0.000 0.167 1.281 0.061 0.062
Mean effects: Zero 0.972 0.011 0.171 1.312 0.074 0.068
Mean effects: Large 0.980 −0.004 0.175 1.315 0.065 0.071
Prior SDs: Small 0.337 0.019 0.163 1.600 0.084 0.093
Prior SDs: Large 1.616 −0.011 0.184 1.027 0.055 0.046
Display 11. Simulation of the resistance to multiple comparisons bias of MBLR. At each simulation, the most significant
treatment × covariate interaction was singled out across all responses by selecting the largest of the GK values (G= 16, K = 5
or 10, GK = 80 or 160) of (estimated interaction coefficient)/(estimated posterior s.d. of coefficient). The MBLR estimates
are unbiased with relatively small RMSE. See text for discussion of other columns.
20 W. DUMOUCHEL
to find the most significant treatment × covariate
interaction among all the responses. There are 16
covariate-based subsets in the model that get inter-
action estimates for every response variable andK =
10 or 5 responses, making a total of 16K = 80 or 160
ratios (estimated interaction coefficient)/(estimated
s.e. of interaction coefficient). The largest ratio (one-
sided alternative) in each MBLR analysis is selected
and then the known true value for the selected in-
teraction is used to compute the accuracy measures.
This selection and assessment is repeated for each
of the 2000 simulations. The first column of Dis-
play 11 is the average of the true coefficients for the
selected interactions. Remembering that the true in-
teractions are generated from a N(0, σ2B + τ
2) dis-
tribution, where
√
(σ2B + τ
2) = either 0.283 (smaller
PSDs) or 1.13 (larger PSDs), it is clear from the
“True Int” column that MBLR is selecting fairly
large interactions. The column headed BIAS con-
tains the average difference between the selected es-
timate and its true value. Remarkably, the MBLR
post-hoc selections have virtually no bias, either over-
all or in any of the six factor-based subsets. The final
four columns in Display 11 show the same accuracy
measures as those of Display 10. The RMSE values
in Display 11 are smaller than any of those in Dis-
play 10, which at first might seem surprising, but is
a consequence of the fact that the maximum of 80
or 160 identically normally distributed variates will
have smaller standard deviation than a single such
variate, due to the short tail of the normal distribu-
tion. The calibration of the posterior standard de-
viations of the selected most significant interaction,
as measured by the values of Z2 and the coverage
probabilities, is not perfect but is similar to that of
the treatment main effects in Display 10(a). This
excellent accuracy of MBLR shrinkage estimates in
the face of post-hoc selection is in spite of the fact
that the variance components which determine the
amount of shrinkage were not known in advance but
were estimated separately for each simulation.
Discussion of the Simulation
It should not be surprising that data generated by
a specific Bayesian model can be better analyzed by
fitting that model. But these simulations show that
there is a surprisingly large advantage to doing so,
and that you give up a lot of efficiency (equivalently
waste clinical resources) by forgoing such an analysis
if, in fact, such a model is realistic. With the RLR
approach, which itself is probably a more efficient
analysis than straight logistic regression, you give
up the possibility of estimating treatment–covariate
interactions and yet still lose accuracy in estimation
of main effects. The principal nonBayesian alterna-
tive is to form a single pooled response, treating the
different issues as equivalent. But then you don’t
even get estimates for the separate issues and you
would be submerging completely the medical dis-
tinction between, say, such a serious adverse event
as Anuria and Dry mouth or Thirst. Our methodol-
ogy is a “Goldilocks alternative” to the bias-variance
trade-off, neither as variable as estimating so many
parameters with no prior shrinkage, nor as biased as
assuming that all issues have the same response to
treatment and that all interactions are 0.
7. SUMMARY AND CONCLUSIONS
Safety issues with low observed frequencies will
produce standard logistic regression estimates with
wide confidence intervals (based on highly variable
sampling distributions). Clinical safety data is often
of very fine granularity. Each observation of a sub-
ject’s adverse event is described with great precision,
providing a great multiplicity of events to be tabu-
lated and whose event frequencies must be compared
across treatment arms. Defining event groupings for
the purpose of getting pooled events with more reli-
able relative frequencies is hard to do in advance, be-
fore the set of somewhat frequent events is observed.
After the data are collected, it can be controver-
sial to lump events together because the selection of
events to pool can determine how significant Treat-
ment/Comparator odds ratios become. The multi-
variate Bayesian logistic regression methodology de-
scribed here is designed to be a compromise between
separate analyses of finely distinguished events and
a single analysis of a pooled event. It requires the
selection of a set of medically related issues, poten-
tially exchangeable with respect to their dependence
on treatment and covariates.
A key concept underlying the proposed methodol-
ogy is that a set of K issues have been prespecified
as important and likely to be biologically and clin-
ically related. It would be a misuse of the method
to try very many subsets of a large set of issues,
stopping only when an “interesting” result is ob-
tained. A similar caution pertains to selection of
covariates—only those with some prior justification
should be included. When too many extraneous co-
variates are entered, the estimated variance compo-
nents may lead to over-shrinking those effects and/or
interactions that are present, and lead to overly nar-
row confidence intervals.
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The methodology is exploratory in nature, in that
the analyst is encouraged to examine the relation-
ship of the adverse event frequencies to multiple
covariates and to treatment by covariate interac-
tions. These more complicated models may not be
estimable by a standard logistic regression algorithm
because the data are often too sparse for the num-
ber of parameters being estimated. Two strategies
are used to cope with this sparsity. First, a Bayesian
model allows the analysis of each issue to borrow
strength from the other issues, assumed medically
related so that this sort of averaging is not unrea-
sonable. The fitting of the MBLR model is accom-
plished by the multiple runs of a maximum like-
lihood algorithm, together with the estimation of
Bayes factors for a range of values of the unknown
variance components. The MBLR algorithm is in-
tended to be able to measure the degree to which the
issues have similar main effects and interactions with
treatment on the logit scale. The hierarchical prior
specification in equations (3)–(5) allows for partial
averaging across issues for those model coefficients
that seem similar. There is also a tendency for the
treatment × covariate interaction coefficients to be
shrunk toward the null value of 0, to an extent con-
trolled by an estimated EB variance parameter as
in (6). This shrinkage is intended to offset the ten-
dency of exploratory methods to find “significant”
subgroup effects purely by chance. Second, a com-
parison method, denoted regularized logistic regres-
sion, sets particular values of the variance compo-
nents in the empirical Bayes model to emulate stan-
dard logistic regression (without interactions) while
avoiding computational problems and inestimable
effects that can be caused by low counts. This mod-
ification is designed to hardly affect the estimates
from standard logistic regression when the data are
not sparse.
Since treatment-by-covariate interaction coeffi-
cients are difficult to interpret, the sums of the treat-
ment main effect plus the covariate interactions are
also presented and interpreted as the estimated treat-
ment effect that would hold for subjects in the sub-
group identified by the covariate value. This com-
bined effect is apropos to the search for a subject
subgroup that might be particularly vulnerable to
an adverse reaction to treatment.
The goal is to allow safety review of a large amount
of clinical data using a sophisticated methodology
that can nevertheless be mastered by those without
advanced training in Bayesian methods or the the-
ory of variance component estimation, or the inter-
pretation of large masses of sparse data. Section 5
shows an example partial analysis of 10 medically
related issues within a pool of 8 studies involving
over 5700 subjects with a model involving treat-
ment, 5 covariates involving 13 defined covariate
values, and including examination of treatment-by-
covariate interactions. Section 6 describes a simula-
tion study that measures the large gains in efficiency
that MBLR can attain, compared to separate analy-
ses for each issue. The striking results in Display 11
show the ability of Bayesian modeling to greatly re-
duce bias due to post-hoc selection of the most sig-
nificant contrast.
The Multivariate Bayesian Logistic Regression is
a technique that can add to the tools available to the
data analyst or medical reviewer. The method does
not eliminate the need for experimental replicabil-
ity and convergence with medical knowledge. A sig-
nificant Bayesian result found in one sample that
is not replicable may just be indicative of a sam-
pling problem. With that said, it is hoped that this
new tool will ease the burden of seeing the forest
for the trees during the analysis of clinical safety
data.
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